Cencora, Inc. (COR) is a Consumer Discretionary stock trading at $307.84 (as of 2026-07-17), with a market capitalization of $59.89B and a trailing P/E of 23.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cencora, Inc. supplies and distributes pharmaceutical products internationally and in the United States. Its segments include distribution and related services for U.S. healthcare providers and retail pharmacies, and offerings supporting biopharmaceutical and healthcare customers such as supply management and software, clinical trial and commercialization support, packaging, and analytics.
Cencora sources and distributes pharmaceutical products, including generic and injectable medications, over-the-counter healthcare products, home healthcare supplies and equipment, plasma and other blood products, vaccines, and other specialty pharmaceutical products, mainly to hospitals, pharmacies, and other healthcare providers in the United States and internationally, generating revenue by distributing and supplying these products and related services to its customers.
Because it is a distributor of pharmaceuticals and specialty products to a wide range of healthcare customers, its profit engine is the volume and mix of delivered drug and specialty product categories across the U.S. and international businesses.
| US Health | $71.7B |
| Intl Health | $7.2B |
Business quality (Mixed): The company operates with U.S. Healthcare Solutions and International Healthcare Solutions, but the provided consolidated versus segment revenue figures do not reconcile perfectly, so segment shares should be treated as approximate based on the given data.
Valuation: At 22× earnings, COR trades 10% below the Wholesale average (24×). Note: one-time items can distort reported P/E.
| Price | $307.84 |
| Market Cap | $59.89B |
| P/E Ratio | 23.5 |
| EV / EBITDA | 17.5 |
| Price / Book | 16.71 |
| Price / Sales | 0.18 |
| FCF Yield | 3.3% |
| DCF Value (model) | $113.69 |
| DCF Upside vs Price | -63.1% |
| Revenue (TTM) | $321.33B |
| Net Margin | 0.5% |
| Revenue Growth (YoY) | 3.8% |
| EPS Growth (YoY) | 128.1% |
| FCF Growth (YoY) | -414.8% |
| Altman Z-Score | 4.82 (safe) |
| Piotroski F-Score | 5/9 (moderate) |
| Stock P/E | 23.5 |
| Sector P/E (Consumer Discretionary) | 21.6 |
| Industry P/E (Wholesale) | 25.2 |
| vs Sector | 9.0% |
| vs Industry | -6.6% |
| Top Institutional Holder | VANGUARD GROUP INC ($7.98B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 9 |
| Sector | Consumer Discretionary |
| Industry | Wholesale |
| CEO | Robert Mauch |
| Employees | 47,000 |
| Country | US |
| IPO Date | 1995-04-04 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.